BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Ultimate Trader

1 year 30%, 2 years 40% and *3 years 40%

*Across 3 years $3395.52 only $1697.76

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,032.38
      0.56%
      US Tech 100
      20,404.40
      0.07%
      Dow Jones
      44,910.65
      0.00%
      Brent Oil
      72.575
      0.69%
      Bitcoin
      95,493.60
      -1.82%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aligos Therapeutics Inc (ALGS)

      7. Aligos Therapeutics Inc (ALGS) News

      Aligos Therapeutics Inc

      Aligos Therapeutics Inc (ALGS)

      NASDAQ
      25.51
      2.52
      (10.96%)
      Closed November 29 4:00PM
      Delayed by 15 minutes
      26.30
      0.79
      ( 3.10% )
      Pre Market: 7:42AM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      ALGS News

      Official News Only

      Form EFFECT - Notice of Effectiveness
      Edgar (US Regulatory)
      November 19 2024
      ALGS (10.96%)

      Form S-3 - Registration statement under Securities Act of 1933
      Edgar (US Regulatory)
      November 06 2024
      ALGS (10.96%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 06 2024
      ALGS (10.96%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 06 2024
      ALGS (10.96%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      October 10 2024
      ALGS (10.96%)

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      September 26 2024
      ALGS (10.96%)

      ALGS Discussion

      View Posts
      tw0122 tw0122 3 weeks ago
      Time to cash in some free shares .$14,62 + 50%
      👍️0
      DewDiligence DewDiligence 3 months ago
      There were no recent insider stock purchases; rather, the three insider transactions dated 9/6/24 were company grants of stock options to the CEO, CFO, and CCO (read the footnotes):

      https://www.sec.gov/Archives/edgar/data/1799448/000161071724000465/xslF345X05/form4.xml (CEO)

      https://www.sec.gov/Archives/edgar/data/1799448/000161071724000466/xslF345X05/form4.xml (CFO)

      https://www.sec.gov/Archives/edgar/data/1799448/000161071724000464/xslF345X05/form4.xml (CSO)
      👍️0
      tw0122 tw0122 3 months ago
      Insider buy at $11.74 and it finally runs
      👍️0
      Monksdream Monksdream 5 months ago
      ALGS new 52 week low
      👍️0
      Monksdream Monksdream 5 months ago
      ALGS new 52 week low
      👍️0
      Monksdream Monksdream 5 months ago
      ALGS new 52 week low
      👍️0
      DewDiligence DewDiligence 7 months ago
      ALGS 1Q24 results:

      https://www.globenewswire.com/news-release/2024/05/07/2877224/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-First-Quarter-2024-Financial-Results.html

      Cash at 3/31/24 was $112.7M, down from $135.7M at 12/31/23.

      No details on when a phase-2 COVID trial, with support from NIH, will start. The PR merely says, “phase-2 enabling activities…are underway.”

      No CC.
      👍️0
      BurgerKing82 BurgerKing82 9 months ago
      Is March 7 a significant catalyst to get in by?
      👍️0
      TheFinalCD TheFinalCD 12 months ago
      $ALGS PHASE 1 NEWS https://finviz.com/quote.ashx?t=ALGS&ty=c&ta=1&p=d

      https://dilutiontracker.com/app/search/ALGS?a=dbb88c
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALGS 3Q23 results:

      https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500015.html

      No CC.
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALGS -15% on warrant-laden $92M financing:

      https://www.globenewswire.com/news-release/2023/10/23/2764690/0/en/Aligos-Therapeutics-Announces-92-Million-Private-Placement-Financing.html
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALGS receives $8.5M NIAID grant for clinical development of ALG-097558:

      https://finance.yahoo.com/news/aligos-therapeutics-announces-award-8-113000446.html

      $8.5M won’t go very far, but I suppose that every little bit helps. ALGS is expected to report data from the phase-1 trial of ALG-097558 in 1H24.
      👍️0
      Monksdream Monksdream 1 year ago
      ALGS new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      ALGS new 52 week low
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALG-055009 phase-2a in NASH expected_to_start 1Q24:

      https://finance.yahoo.com/news/aligos-therapeutics-announces-ind-clearance-113000003.html

      ALG-055009 is a thyroid hormone receptor beta agonist.
      👍️0
      Monksdream Monksdream 1 year ago
      ALGS new 52 week low
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALGS, JNJ reach agreement in principle to settle pending litigation:

      https://www.sec.gov/ix?doc=/Archives/edgar/data/0001799448/000119312523200617/d538755d8k.htm

      The terms will presumably be disclosed when the settlement in finalized.
      👍️0
      DewDiligence DewDiligence 1 year ago
      The relatively low cash burn in 2Q23 was due to ALGS’ slashing R&D expenses by more than half relative to 2Q22 ($17M in 2Q23 vs 2Q22 $35M).
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALGS 2Q23 results—6/30/23 cash=$91M—(down $15M from 3/31/23):

      https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500975.html

      Data from the phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, are expected in 1H24. The trial, which is being conducted in the UK, is currently in the SAD phase.

      No CC.
      👍️0
      DewDiligence DewDiligence 1 year ago
      ALGS HBV data at EASL:

      https://www.globenewswire.com/news-release/2023/06/21/2692513/0/en/Aligos-Therapeutics-Presents-Data-from-its-Liver-Disease-Programs-at-the-European-Association-for-the-Study-of-the-Liver-EASL-Congress-2023.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS +51%/AH on collaboration with Chinese company:

      https://finance.yahoo.com/news/aligos-therapeutics-announces-research-collaboration-210500298.html Under the terms of the agreement, Aligos and Amoytop* will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales. Before the AH pop, ALGS’ enterprise value was deeply negative; after the AH pop, the EV is still negative but less so.

      The up-front cash amount is presumably tiny since it wasn’t disclosed.

      *Xiamen Amoytop Biotech Company Ltd.
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS 1Q23 results—3/31/22 cash=$104M, down from $126M at 12/31/22:

      https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500905.html

      ALGS expects to start a phase-1 trial of ALG-097558, a SARS-CoV-2 protease inhibitor, in the UK in mid 2023.

      No CC.
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS 4Q22 results—12/31/22 cash=$126M—4Q22 cash_burn=$16M:

      https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-210500130.html

      ALGS’ COVID protease inhibitor, ALG-097558, is expected to start phase-1 in 2Q23.

      No CC.
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS “de-prioritizes” HBV program—reduces workforce 10%:

      https://finance.yahoo.com/news/aligos-therapeutics-announces-strategic-reprioritization-210500405.html Aligos Therapeutics…today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck…

      Additionally, the Company plans to complete the <=48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

      This portfolio reprioritization is being accompanied by a reduction of the Company’s current workforce of approximately 10%...

      …As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024. In other words, the HBV program is getting the axe. After completing the early-stage HBV trials in progress, ALGS will offload these assets (if anyone wants them) or simply shut down the program.

      The stock is flattish in the AH session.
      👍️0
      Laster Laster 2 years ago
      Might hit $3 today.
      Easily moving to $5.
      Discussed this on HEPA board at under $1 in December.
      Wow.
      Yippee.
      👍️0
      Laster Laster 2 years ago
      Beautiful. Will pass $2 today.
      Best NASH play out there.
      Good luck.
      👍️0
      Laster Laster 2 years ago
      It’s running.
      Amazing NASH stock.
      $1.20.
      $3 in February.
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS provides 2023 roadmap:

      https://www.globenewswire.com/news-release/2023/01/05/2583624/0/en/Aligos-Therapeutics-on-Track-to-Complete-Phase-2-Enabling-Activities-in-2023-for-its-Clinically-Validated-THR-%C3%9F-Drug-Candidate-for-NASH-ALG-055009.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS 3Q22 results—9/30/22 cash=$142M—3Q22 cash_burn=$17M:

      https://www.globenewswire.com/news-release/2022/11/02/2547039/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Third-Quarter-2022-Financial-Results.html

      ALGS’ COVID protease inhibitor, ALG-097558 is expected to start phase-1 in 2Q23.

      No CC.
      👍️0
      DewDiligence DewDiligence 2 years ago
      ALGS 2Q22 results—6/30/22 cash=$159.3M—(down from $183M @3/31/22):

      https://www.globenewswire.com/news-release/2022/08/04/2492772/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2022-Financial-Results.html

      Phase-1 for the SARS-CoV-2 protease inhibitor, ALG-097558 has been delayed and is now expected to start in 2023, following a CTA filing in 1Q23. (The prior guidance was for an IND filing in 2H22.)
      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS—Cash @3/31/22=$183M—$23B burn in 1Q22:

      https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500766.html

      Other than the financials, there is no new news. ALGS still plans to start phase-1 for its COVID protease inhibitor in late 2022 or early 2023 (i.e. IND filing in 2H22).

      No CC.
      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS selects lead SARS-CoV-2 PI—phase-1 expected to start in early 2023 (or very late 2022):

      https://finance.yahoo.com/news/aligos-therapeutics-selects-drug-candidate-120000412.html

      The timing of this program was known from the Leerink webcast two months ago (#msg-167924816), so the only new news is that a lead compound has been selected.
      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS discontinues another HBV candidate:

      https://finance.yahoo.com/news/aligos-discontinues-development-antisense-oligonucleotide-120000830.html Aligos Therapeutics…today announced that it has discontinued development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

      Dosing in the first CHB cohort of Study ALG-020572-401 (NCT05001022) was stopped after one subject experienced a serious adverse event (SAE) with significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization. This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares…
      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS 4Q21 financials—12/31/21_cash=$205.8M:

      https://finance.yahoo.com/news/aligos-therapeutics-reports-fourth-quarter-210500703.html

      No CC.
      👍️0
      DewDiligence DewDiligence 3 years ago
      Disclosure: I'm long ENTA.
      👍️0
      DewDiligence DewDiligence 3 years ago
      Two takeaways from today's Leerink webcast on ALGS-9711 (oral coronavirus protease inhibitor): 1) ALGS-097111 phase-1 won’t start until 2023 (insofar as the IND is expected to be filed in late 2022); 2) CEO Blatt talked up combination therapy to treat COVID even while insisting compound is “best in class,” which I find curious.
      👍️0
      DewDiligence DewDiligence 3 years ago
      Preclinical data on ALGS-097111 protease inhibitor from 2021 CROI:

      https://www.aligos.com/wp-content/uploads/2021/03/CROI21_Science-Spotlight_ID2675_Vandyck_handout_1.pdf
      👍️0
      DewDiligence DewDiligence 3 years ago
      Link to Leerink webcast:

      https://wsw.com/webcast/svbleerink67/enta/2640400
      👍️0
      oxnous oxnous 3 years ago
      ALGS--Bungee Jumping

      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS -40%/PM on_discontinuation_of_lead HBV candidate for_lack_of_efficacy:

      https://finance.yahoo.com/news/aligos-halting-further-development-stops-130000126.html
      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS—(-16%)—sells 5.06M* shares @$19.00—a 20% discount to Monday’s close:

      https://finance.yahoo.com/news/aligos-therapeutics-announces-pricing-83-020800387.html

      *Assuming exercise of underwriter’s option.
      👍️0
      DewDiligence DewDiligence 3 years ago
      ALGS—(-11%)—presents EASL HBV lineup:

      https://finance.yahoo.com/news/aligos-therapeutics-announces-pipeline-upcoming-120000870.html

      Nothing in this PR is especially newsworthy, so I’m not sure why the stock is selling off today. Maybe some investors were expecting some kind of big announcement.
      👍️0

      Your Recent History

      NASDAQ
      ALGS
      Aligos Therapeutics
      Delayed Upgrade Clock